TCR2 THERAPEUTICS INC. Annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD from 2018 to 2022
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
-
Summary
-
Tcr2 Therapeutics Inc. quarterly/annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent history and growth rate from 2018 to 2022.
- Tcr2 Therapeutics Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending March 31, 2023 was -$40.1M, a 36.3% decline year-over-year.
- Tcr2 Therapeutics Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the twelve months ending March 31, 2023 was -$163M, a 51.3% decline year-over-year.
- Tcr2 Therapeutics Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2022 was -$152M, a 52.4% decline from 2021.
- Tcr2 Therapeutics Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2021 was -$99.9M, a 48.6% decline from 2020.
- Tcr2 Therapeutics Inc. annual Comprehensive Income (Loss), Net of Tax, Attributable to Parent for 2020 was -$67.2M, a 41.9% decline from 2019.
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Trailing 12 Months (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Annual (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Annual Growth (%)